Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.

Arribas JR, Thompson M, Sax PE, et al. J Acquir Immune Defic Syndr. 2017;75(2):211-218.

Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.

Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104. 

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort.

Cuzin L, Cotte L, Delpierre C, et al. PLoS One. 2019;14(9):e0222067.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association.

Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.

Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation.

Ford S, Crauwels H, Han K, et al. CROI. Virtual Meeting. March 8-11, 2020. Abstract 466.

Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.

Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.

Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.

Lagathu C, Béréziat V, Gorwood J, et al. Expert Opin Drug Saf. 2019;18(9):829-840.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Rapid initiation of antiretroviral therapy for people living with HIV.

Mateo-Urdiales A, Johnson S, Smith R, et al. Cochrane Database Syst Rev. 2019;6(6):CD012962. 

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.

Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.

Ryom L, Cotter A, De Miguel R, et al. HIV Med. 2020;21(10):617-624.

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.

Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1379-1389.

Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.

Segal-Maurer S, Castagna A, Berhe M, et al.  CROI. March 6-10, 2021; Virtual Conference. Abstract 127.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.